JP6155285B2 - Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド - Google Patents

Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド Download PDF

Info

Publication number
JP6155285B2
JP6155285B2 JP2014557739A JP2014557739A JP6155285B2 JP 6155285 B2 JP6155285 B2 JP 6155285B2 JP 2014557739 A JP2014557739 A JP 2014557739A JP 2014557739 A JP2014557739 A JP 2014557739A JP 6155285 B2 JP6155285 B2 JP 6155285B2
Authority
JP
Japan
Prior art keywords
mmol
cyclopenta
pentamethyl
prop
mixture
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014557739A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015510515A5 (enExample
JP2015510515A (ja
Inventor
ジェイコブ・スウィドースキ
ニコラス・エイ・ミーンウェル
アリシア・レゲイロ−レン
シン−ユエン・シット
チェン・ジエ
ヤン・チェン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bristol Myers Squibb Co
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48946098&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP6155285(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of JP2015510515A publication Critical patent/JP2015510515A/ja
Publication of JP2015510515A5 publication Critical patent/JP2015510515A5/ja
Application granted granted Critical
Publication of JP6155285B2 publication Critical patent/JP6155285B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J53/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
    • C07J53/002Carbocyclic rings fused
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J63/00Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2014557739A 2012-02-15 2013-02-13 Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド Active JP6155285B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US61/599,040 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US13/760,726 2013-02-06
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Publications (3)

Publication Number Publication Date
JP2015510515A JP2015510515A (ja) 2015-04-09
JP2015510515A5 JP2015510515A5 (enExample) 2016-03-17
JP6155285B2 true JP6155285B2 (ja) 2017-06-28

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557739A Active JP6155285B2 (ja) 2012-02-15 2013-02-13 Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド

Country Status (26)

Country Link
US (1) US8906889B2 (enExample)
EP (1) EP2814834B1 (enExample)
JP (1) JP6155285B2 (enExample)
KR (1) KR20140123584A (enExample)
CN (2) CN106046106A (enExample)
AR (1) AR089996A1 (enExample)
AU (1) AU2013221725B2 (enExample)
BR (1) BR112014019672A8 (enExample)
CA (1) CA2864656A1 (enExample)
CL (1) CL2014002141A1 (enExample)
CO (1) CO7061077A2 (enExample)
EA (1) EA024361B1 (enExample)
ES (1) ES2656984T3 (enExample)
HK (1) HK1204608A1 (enExample)
IL (1) IL234077A (enExample)
MX (1) MX2014009235A (enExample)
MY (1) MY166793A (enExample)
NZ (1) NZ631408A (enExample)
PE (1) PE20142315A1 (enExample)
PH (1) PH12014501816A1 (enExample)
PT (1) PT2814834T (enExample)
SG (1) SG11201404748XA (enExample)
TW (1) TW201336863A (enExample)
UY (1) UY34627A (enExample)
WO (1) WO2013123019A1 (enExample)
ZA (1) ZA201406724B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
JP6186010B2 (ja) 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類
MA39374A1 (fr) 2014-04-11 2018-06-29 Viiv Healthcare Uk No 4 Ltd Triterpénoïdes présentant une activité d'inhibition de la maturation du vih, substitués en 3ème position par un cycle non aromatique portant un substituant halogénoalkyle
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
RU2017118576A (ru) 2014-11-14 2018-12-14 ВАЙВ ХЕЛТКЕР ЮКей (N5) ЛИМИТЕД C-17-арил-замещённые аналоги бетулиновой кислоты
WO2016077572A1 (en) * 2014-11-14 2016-05-19 Bristol-Myers Squibb Company Extended betulinic acid analogs
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
KR20170135970A (ko) * 2015-04-14 2017-12-08 비브 헬스케어 유케이 (넘버4) 리미티드 Hiv 성숙화 억제제를 생산하는 방법
KR20180028534A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
RU2018105352A (ru) 2015-07-28 2019-08-29 ГлаксоСмитКлайн Интеллекчуал Проперти (N2) Лимитед Производные бетулина для предупреждения или лечения ВИЧ-инфекций
CN108368071A (zh) 2015-09-24 2018-08-03 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的化合物
CN108699103A (zh) * 2016-01-20 2018-10-23 葛兰素史克知识产权第二有限公司 具有hiv成熟抑制活性的羽扇烷类的胺衍生物
AR107512A1 (es) * 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
JP7670482B2 (ja) * 2017-09-13 2025-04-30 エミオン インコーポレイテッド ウルソール酸モルホリン塩及びジエタノールアミン塩
WO2019207460A1 (en) 2018-04-24 2019-10-31 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
MX2021009584A (es) 2019-02-11 2021-09-23 Hetero Labs Ltd Nuevos derivados de triterpeno como inhibidores del virus de la inmunodeficiencia humana (vih).
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
JP2007529544A (ja) 2004-03-17 2007-10-25 パナコス ファーマシューティカルズ, インコーポレイテッド 3−o−(3’,3’−ジメチルスクシニル)ベツリン酸の製薬的な塩
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
US20090062243A1 (en) 2007-08-03 2009-03-05 Advanced Life Sciences, Inc. Lupane-Type Triterpenoids Modified at 30-Position and Analogues Thereof
MX2010007375A (es) * 2008-01-03 2010-09-30 Virochem Pharma Inc Nuevos derivados de lupano.
CA2714049A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17.beta. lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
MX2012007154A (es) 2009-12-17 2012-08-01 Merck Sharp & Dohme Aminopirimidinas como inhibidores de syk.
ES2612452T3 (es) * 2010-06-04 2017-05-17 VIIV Healthcare UK (No.5) Limited Derivados de ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576586B1 (en) * 2010-06-04 2015-08-12 Bristol-Myers Squibb Company C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
US9102614B2 (en) 2010-07-02 2015-08-11 Gilead Sciences, Inc. Naphth-2-ylacetic acid derivatives to treat AIDS
ES2653847T3 (es) * 2011-01-31 2018-02-09 Viiv Healthcare Uk (No. 4) Limited Triterpenoides C-17 y C-3 modificados con actividad inhibitoria contra maduración del VIH
CN103339141B (zh) 2011-01-31 2016-08-24 百时美施贵宝公司 作为hiv成熟抑制剂的c-3修饰的桦木酸衍生物的c-28胺
ES2611727T3 (es) 2011-09-21 2017-05-10 VIIV Healthcare UK (No.5) Limited Derivados de ácido betulínico novedosos con actividad antivírica
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
JP6186010B2 (ja) * 2013-02-06 2017-08-23 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company Hiv成熟阻害活性を有するc−19修飾トリテルペノイド類

Also Published As

Publication number Publication date
PE20142315A1 (es) 2015-01-16
AR089996A1 (es) 2014-10-01
US8906889B2 (en) 2014-12-09
UY34627A (es) 2013-09-02
US20130210787A1 (en) 2013-08-15
EA201491531A1 (ru) 2014-11-28
PH12014501816A1 (en) 2014-11-17
SG11201404748XA (en) 2014-09-26
MX2014009235A (es) 2014-11-10
CN104220451A (zh) 2014-12-17
KR20140123584A (ko) 2014-10-22
IL234077A (en) 2016-11-30
EP2814834A1 (en) 2014-12-24
TW201336863A (zh) 2013-09-16
JP2015510515A (ja) 2015-04-09
HK1204608A1 (en) 2015-11-27
EP2814834B1 (en) 2017-09-13
CO7061077A2 (es) 2014-09-19
AU2013221725A1 (en) 2014-10-02
CN104220451B (zh) 2016-06-29
CA2864656A1 (en) 2013-08-22
EA024361B1 (ru) 2016-09-30
ES2656984T3 (es) 2018-03-01
ZA201406724B (en) 2016-08-31
BR112014019672A8 (pt) 2017-07-11
PT2814834T (pt) 2017-12-06
WO2013123019A1 (en) 2013-08-22
CN106046106A (zh) 2016-10-26
CL2014002141A1 (es) 2014-10-03
BR112014019672A2 (enExample) 2017-06-20
MY166793A (en) 2018-07-23
AU2013221725B2 (en) 2016-10-27
IL234077A0 (en) 2014-09-30
NZ631408A (en) 2015-06-26

Similar Documents

Publication Publication Date Title
JP6155285B2 (ja) Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド
JP6186012B2 (ja) C−3アルキルおよびアルケニル修飾ベツリン酸誘導体
CA2801491C (en) C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors
JP6212545B2 (ja) Hiv成熟阻害活性を有するc−17二環式アミンのトリテルペノイド
US11464790B2 (en) Triterpenoids with HIV maturation inhibitory activity
HK40041853A (en) Triterpenoids with hiv maturation inhibitory activity
HK1232548B (en) Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160125

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20160125

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170202

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20170509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170530

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170605

R150 Certificate of patent or registration of utility model

Ref document number: 6155285

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250